Daniel J Cantillon1, Derek V Exner2, Nima Badie3, Kevin Davis3, Ning Yan Gu3, Yelena Nabutovsky3, Rahul Doshi4. 1. Cleveland Clinic, Heart and Vascular Institute, Cleveland, Ohio. Electronic address: cantild@ccf.org. 2. Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada. 3. Abbott Laboratories, Abbott Park, Illinois. 4. Keck Hospital of the University of Southern California, Los Angeles, California.
Abstract
OBJECTIVES: The aim of this study was to retrospectively characterize transvenous pacemaker (TVP) complications and associated health care costs in a large-scale U.S. patient cohort. BACKGROUND: TVP complications have previously been shown to affect more than 1 in 10 patients but may be underestimated. Pacemakers are widely implanted across community and urban hospitals by operators of varying specialization and experience. METHODS: Truven Health MarketScan databases track U.S. health care claims and encounters of private or Medicare supplemental insurance. Patients implanted with de dual- and single-chamber TVPs between April 2010 and March 2014 and over 1 year of pre-implantation MarketScan enrollment were identified. International Classification of Diseases-Ninth Revision and Current Procedural Terminology codes were used to extract relevant comorbidities and complications. Incremental adjusted cost analysis was performed for acute complications, defined as those occurring within 30 days of implantation. RESULTS: Among 72,701 TVP implantations (mean age 75 ± 12 years, 55% men, 13% single chamber) with 1.5 ± 1.1 years of follow-up, acute complications (0 to 1 month) occurred in 7.7% of single- and 9.1% of dual-chamber TVPs and long-term complications (1 to 36 months) in 6.4% and 5.9% of single- and dual-chamber TVPs, respectively. The net 3-year event rates were approximately 15% and 16%. The incidence and incremental cost of complications are considerable. Most common acute complications include thoracic trauma (3.71%, $70,114), leads requiring revision (3.51%, $9,296), and infection (1.15%, $80,247). Long-term complications are attributed to leads (2.84%), infection (2.42%), and pocket (0.96%). CONCLUSIONS: Claims data suggest that TVP complications are more common than previously reported, affecting nearly 1 in 6 patients by 3 years and contributing to considerable incremental U.S. health care cost.
OBJECTIVES: The aim of this study was to retrospectively characterize transvenous pacemaker (TVP) complications and associated health care costs in a large-scale U.S. patient cohort. BACKGROUND:TVP complications have previously been shown to affect more than 1 in 10 patients but may be underestimated. Pacemakers are widely implanted across community and urban hospitals by operators of varying specialization and experience. METHODS: Truven Health MarketScan databases track U.S. health care claims and encounters of private or Medicare supplemental insurance. Patients implanted with de dual- and single-chamber TVPs between April 2010 and March 2014 and over 1 year of pre-implantation MarketScan enrollment were identified. International Classification of Diseases-Ninth Revision and Current Procedural Terminology codes were used to extract relevant comorbidities and complications. Incremental adjusted cost analysis was performed for acute complications, defined as those occurring within 30 days of implantation. RESULTS: Among 72,701 TVP implantations (mean age 75 ± 12 years, 55% men, 13% single chamber) with 1.5 ± 1.1 years of follow-up, acute complications (0 to 1 month) occurred in 7.7% of single- and 9.1% of dual-chamber TVPs and long-term complications (1 to 36 months) in 6.4% and 5.9% of single- and dual-chamber TVPs, respectively. The net 3-year event rates were approximately 15% and 16%. The incidence and incremental cost of complications are considerable. Most common acute complications include thoracic trauma (3.71%, $70,114), leads requiring revision (3.51%, $9,296), and infection (1.15%, $80,247). Long-term complications are attributed to leads (2.84%), infection (2.42%), and pocket (0.96%). CONCLUSIONS: Claims data suggest that TVP complications are more common than previously reported, affecting nearly 1 in 6 patients by 3 years and contributing to considerable incremental U.S. health care cost.
Authors: Jared P Beller; Zachary Tyerman; J Hunter Mehaffey; Robert B Hawkins; Eric J Charles; Leora T Yarboro; Nicholas R Teman; Tanya Wancheck; Gorav Ailawadi; Nishaki K Mehta Journal: J Surg Res Date: 2020-12-03 Impact factor: 2.192
Authors: Naoki Misumida; Mariah Pagath; Gbolahan O Ogunbayo; Ryan E Wilson; Sun Moon Kim; Ahmed Abdel-Latif; Claude S Elayi Journal: Catheter Cardiovasc Interv Date: 2018-10-09 Impact factor: 2.692
Authors: Nick B Spath; Kelvin Wang; Sowmya Venkatasumbramanian; Omar Fersia; David E Newby; Chris Ce Lang; Neil R Grubb; Marc R Dweck Journal: Open Heart Date: 2019-02-09
Authors: Naoki Misumida; Gbolahan O Ogunbayo; John Catanzaro; Farshid Etaee; Sun Moon Kim; Ahmed Abdel-Latif; Khaled M Ziada; Claude S Elayi Journal: Clin Cardiol Date: 2019-06-07 Impact factor: 2.882
Authors: Mikhael F El-Chami; Timothy Shinn; Sundeep Bansal; Jose L Martinez-Sande; Nicolas Clementy; Ralph Augostini; Bipin Ravindran; Venkata Sagi; Hemanth Ramanna; Christophe Garweg; Paul R Roberts; Kyoko Soejima; Kurt Stromberg; Dedra H Fagan; Nicky Zuniga; Jonathan P Piccini Journal: J Cardiovasc Electrophysiol Date: 2021-01-23